Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR3 | O60755 | 1/20 | 0.61 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.61 |
| ▸ | EGFR | P00533 | 15/20 | 0.59 |
| ▸ | TNF | P01375 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | KRAS | P01116 | 1/20 | 0.52 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 2/20 | 0.52 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29853404 | 0.78 | GALR3 (0.62) | GALR3NR2F2EGFRTNFRAB9A | |
| SCHEMBL6268307 | 0.78 | GALR3 (0.62) | GALR3NR2F2EGFRTNFRAB9A | |
| SCHEMBL22524223 | 0.78 | EGFR (0.66) | GALR3NR2F2EGFR | |
| SCHEMBL22524264 | 0.78 | EGFR (0.66) | GALR3NR2F2EGFR | |
| SCHEMBL22524279 | 0.78 | EGFR (0.66) | GALR3NR2F2EGFR | |
| SCHEMBL24453350 | 0.78 | EGFR (0.66) | GALR3NR2F2EGFR | |
| SCHEMBL5312802 | 0.76 | GALR3 (1.00) | GALR3NR2F2EGFRTNFRAB9A | |
| SCHEMBL17181108 | 0.76 | GALR3 (1.00) | GALR3NR2F2EGFRTNFRAB9A | |
| SCHEMBL7648472 | 0.75 | GALR3 (0.70) | GALR3NR2F2EGFRTNFRAB9A | |
| SCHEMBL7493588 | 0.73 | EGFR (0.67) | GALR3NR2F2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390805-B2 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2008-06-24 | — | — | US | disclosed |
| US-7323469-B2 | 7H-pyrrolo[2,3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2008-01-29 | — | — | US | disclosed |
| US-20070161632-A1 | 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | BOLD GUIDO | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161632-A1 | 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | TYMP, DPYD, CCND2 | GALR3 4699/4885NR2F2 2371/4885EGFR 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.